Lali Sharvadze
Overview
Explore the profile of Lali Sharvadze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baliashvili D, Blumberg H, Gandhi N, Averhoff F, Benkeser D, Shadaker S, et al.
PLoS Med
. 2023 May;
20(5):e1004121.
PMID: 37141386
Background: The Eastern European country of Georgia initiated a nationwide hepatitis C virus (HCV) elimination program in 2015 to address a high burden of infection. Screening for HCV infection through...
2.
Dolmazashvili E, Sharvadze L, Abutidze A, Chkhartishvili N, Todua M, Adamia E, et al.
Clin Liver Dis (Hoboken)
. 2022 Nov;
20(5):175-178.
PMID: 36447909
Content available: Audio Recording.
3.
Borkowska T, Chkhartishvili N, Karkashadze E, Chokoshvili O, Gabunia P, Sharvadze L, et al.
PLoS One
. 2022 Oct;
17(10):e0276749.
PMID: 36301817
Background: Life expectancy and quality of life of people living with HIV have been dramatically improved after introducing antiretroviral therapy, and the prevalence of non-communicable diseases has increased. Several studies...
4.
Baliashvili D, Blumberg H, Benkeser D, Kempker R, Shadaker S, Averhoff F, et al.
Clin Infect Dis
. 2022 Sep;
76(2):245-251.
PMID: 36134743
Background: Hepatitis C virus (HCV) infection causes dysregulation and suppression of immune pathways involved in the control of tuberculosis (TB) infection. However, data on the role of chronic hepatitis C...
5.
Tskhomelidze I, Shadaker S, Kuchuloria T, Gvinjilia L, Butsashvili M, Nasrullah M, et al.
Liver Int
. 2022 Sep;
43(3):558-568.
PMID: 36129625
Background And Aims: In 2015, the country of Georgia launched an elimination program aiming to reduce the prevalence of Hepatitis C virus (HCV) infection by 90% from 5.4% prevalence (~150 ...
6.
Boeke C, Hiebert L, Waked I, Tsertsvadze T, Sharvadze L, Butsashvili M, et al.
Clin Infect Dis
. 2021 May;
74(3):513-516.
PMID: 34014252
Access to recommended second-line treatments is limited for patients who fail initial hepatitis C virus (HCV) therapy in low- and middle-income countries. Alternative regimens and associated outcomes are not well...
7.
Rukhadze N, Kirk O, Chkhartishvili N, Bolokadze N, Sharvadze L, Gabunia P, et al.
Int J STD AIDS
. 2021 Feb;
32(7):662-670.
PMID: 33612013
We assessed trends in causes and outcomes of hospitalization among people living with HIV (PLWH) admitted to the Infectious Diseases, AIDS and Clinical Immunology Research Center (IDACIRC) in Tbilisi, Georgia....
8.
Harris A, Chokoshvili O, Biddle J, Turashvili K, Japaridze M, Burjanadze I, et al.
BMC Public Health
. 2020 Apr;
19(Suppl 3):466.
PMID: 32326938
Background: The country of Georgia has a high burden of chronic hepatitis C virus (HCV) infection, and prisoners are disproportionately affected. During 2013, a novel program offering no cost screening...
9.
Tsertsvadze T, Gamkrelidze A, Nasrullah M, Sharvadze L, Morgan J, Shadaker S, et al.
BMC Infect Dis
. 2020 Jan;
20(1):30.
PMID: 31924172
Background: Georgia has one of the highest HCV prevalence in the world and launched the world's first national HCV elimination programs in 2015. Georgia set the ambitious target of diagnosing...
10.
Walker J, Kuchuloria T, Sergeenko D, Fraser H, Lim A, Shadaker S, et al.
Lancet Glob Health
. 2019 Dec;
8(2):e244-e253.
PMID: 31864917
Background: Georgia has a high prevalence of hepatitis C, with 5·4% of adults chronically infected. On April 28, 2015, Georgia launched a national programme to eliminate hepatitis C by 2020...